Anchor Investment Management LLC Purchases 78 Shares of Danaher Co. (NYSE:DHR)

Anchor Investment Management LLC boosted its position in Danaher Co. (NYSE:DHR) by 1.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,039 shares of the conglomerate’s stock after purchasing an additional 78 shares during the period. Anchor Investment Management LLC’s holdings in Danaher were worth $1,679,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. CarsonAllaria Wealth Management Ltd. purchased a new position in Danaher during the second quarter valued at $25,000. nVerses Capital LLC purchased a new position in shares of Danaher during the 2nd quarter valued at about $25,000. Teachers Insurance & Annuity Association of America purchased a new stake in Danaher in the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher during the 3rd quarter worth approximately $40,000. Finally, FSA Wealth Management LLC purchased a new position in Danaher during the third quarter valued at approximately $50,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

Danaher stock opened at $234.50 on Friday. Danaher Co. has a 1 year low of $219.15 and a 1 year high of $281.70. The firm has a 50-day moving average of $248.34 and a two-hundred day moving average of $257.78. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The stock has a market cap of $169.37 billion, a price-to-earnings ratio of 44.75, a price-to-earnings-growth ratio of 4.33 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the company earned $2.02 EPS. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. On average, research analysts forecast that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analysts Set New Price Targets

Several analysts have recently commented on DHR shares. Raymond James decreased their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Stephens reaffirmed an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. KeyCorp lifted their target price on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Wells Fargo & Company assumed coverage on Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target for the company. Finally, Royal Bank of Canada lowered their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.